Effect of taxol on the expression of FoxM1 ovarian cancer-associated gene

Abstract

The incidence of ovarian cancer in women has been on the increase in recent years. The aim of the present study was to examine the effects of taxol on the expression of ovarian cancer-associated gene forkhead box transcription factor M1 (FoxM1) and its therapeutic effects for ovarian cancer. The expression of FoxM1 gene was examined in patients with or without ovarian cancer. RNA and protein levels of FoxM1 gene of ovarian cancer patients were detected at different time periods (1, 3, 6, 8, 12 and 24 months) after treatment with taxol. The results showed that the mRNA level of FoxM1 gene in patients with ovarian cancer was significantly higher than that in normal women (P<0.05). With time and progression of the disease, the expression of FoxM1 gene significantly increased in the patients not being administered taxol, whereas the expression of FoxM1 in the patients administered taxol was significantly lower comparatively (P<0.05). In conclusion, an asssociation was identified between the FoxM1 gene and ovarian cancer. The FoxM1 gene therefore promotes the generation and deterioration of ovarian cancer, whereas taxol reduces it. These findings provide a certain theoretical basis for the later treatment of ovarian cancer disease.

Astragalus Polysaccharide RAP Selectively Attenuates Paclitaxel-Induced Cytotoxicity Toward RAW 264.7 Cells by Reversing Cell Cycle Arrest and Apoptosis

“…It also disrupts the cytoskeletal framework that is necessary for tumor cell replication and metastatic spread (Magidson et al, 2016; Zhang et al, 2018), and this disruption subsequently triggers cancer cell death not only in mitotic arrest state, but also after mitotic slippage to an abnormal G1 (Zhu et al, 2014). Taxol has been commonly prescribed to treat a variety of tumors, particularly ovarian and breast cancer (Reichman et al, 1993; Kampan et al, 2015; Notte et al, 2015; Bo et al, 2016; Liu et al, 2016).…”